Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.

• Status: Terminated
• Trial end date: 2004-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the two studies is to determine whether an experimental therapy using a photoactive drug, verteporfin, in combination with direct light exposure of basal cell carcinoma of the skin can safely eliminate these skin tumors.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: QLT Inc.
• Collaborator: Novartis
• Treatments: Verteporfin

Criteria

Inclusion Criteria:

• Currently has at least 3 eligible BCC skin tumors that have never been treated

• Is willing to have these tumor sites surgically removed

Exclusion Criteria:

• Has xeroderma pigmentosum

• Has BCC tumors that are the result of prior radiotherapy or immunosuppression due to an organ transplant

• Is immunosuppressed

• Has abnormal liver function

• Is receiving systemic chemotherapy or has received chemotherapy within the last two years